Navigation Links
CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS

CytoDyn, Inc. is preparing for its next clinical trial of Cytolin, the breakthrough drug for HIV/AIDS that uses the body's own immune system to fight the virus. The preparations come at a time when CytoDyn, Inc. is making big changes that include relocating to a larger facility to accommodate expanded business activities.

(PRWEB) October 22, 2008 -- Although HIV and AIDS are substantially more treatable now than during the height of the AIDS epidemic in the 1980s, numerous challenges still face AIDS and HIV patients and AIDS researchers. One major concern is that drug-resistant strains of HIV are emerging globally, but there is hope that Cytolin, a first-in-class AIDS and HIV treatment from CytoDyn, Inc., can help address this problem.

A new clinical trial to reinvestigate dosing specifications for Cytolin will be conducted in San Francisco, California, by Dr. Jay Lalezari, a leading AIDS researcher. The study will be managed by New York City-based Target Health, Inc., which CytoDyn, Inc. has retained to serve as its contract research organization for the project.

Cytolin is based on a decade of progress in immunology. Community physicians used the drug experimentally at the height of the AIDS epidemic to rescue patients when no effective antiviral treatments had yet been approved for people with AIDS.

"We're excited about the progress we've made in preparing for the next clinical trial of Cytolin," explains Dr. Nadar Pourhassan, Chief Operating Officer of CytoDyn, Inc. "We should soon be prepared to show those unfamiliar with a decade of progress in immunology that science has the solution to multi-drug resistance in HIV/AIDS and, perhaps, other infectious diseases."

Cytolin is a unique treatment for AIDS because it utilizes the immune systems of its users to control HIV infection. Strong immune systems typically control all viruses regardless of their subspecies, which suggests the potential for Cytolin to serve as an effective therapy for HIV/AIDS patients who are failing antiretroviral treatment. The drug may also help suppress drug resistant forms of HIV when used in conjunction with a successfu antiretroviral treatment for AIDS.

Allen D. Allen, Chief Executive Officer of CytoDyn, Inc., says the company philosophy is to maintain complete transparency in its operations. Visitors to can view the Company's financial records, share price, and a summary that explains the science behind Cytolin with key references to the literature.

"An enduring recovery of the global economy depends upon capitalists ending their love affair with smoke-and-mirrors, and investing in reality instead of perceptions," says Allen D. Allen, Chief Executive Officer of CytoDyn, Inc. "Unfortunately, innumeracy has to end first, and we hope to contribute to some progress in that regard."

In addition to the upcoming trial of Cytolin, CytoDyn, Inc. is announcing the relocation of its offices to 1511 Third St., Santa Fe, New Mexico. The expanded offices will accommodate new staff members who will be bringing the company's periodic filings up to date.

To learn more about CytoDyn, Inc., the upcoming clinical trials for Cytolin and how Cytolin may be used as an adjunct for antiretroviral treatments for AIDS, visit

Disclaimer: This press release contains forward-looking statements that are not historical facts. CytoDyn's management makes forward-looking statements concerning the Company's expected future operations, performance and other developments. These forward-looking statements are necessarily estimates based upon current information and projections and involve a number of risks and uncertainties, including but not limited to, the failure of preliminary results from clinical studies to reflect the results from more comprehensive studies. There can be no assurance that such risks and uncertainties, or other factors, will not affect the accuracy of such forward-looking statements. It is impossible to identify all the factors that could cause actual results to differ materially from those estimated by CytoDyn. They include, but are not limited to, government regulation, managing and maintaining growth, victimization by white-collar offenders, and the effects of adverse publicity, litigation, competition, and other factors that may be identified from time to time in the Company's announcements.

About CytoDyn, Inc.:
CytoDyn, Inc. is a drug manufacturing firm specializing in new, novel forms of AIDS and HIV treatment drugs. The company is best known for Cytolin, a drug that represents major advances in the treatment of HIV/AIDS. Cytolin offers an alternative by using the immune systems of those suffering from HIV/AIDS, in contrast to using antiretroviral agents to suppress the infection.


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Gilbert Hospital Prepares for Flu Season
2. American Red Cross Prepares for Tropical Storm Fay in Florida
3. New Anti-Cellulite Treatment Prepares Women for Falls Short Skirts
4. New Anti-Cellulite Treatment Prepares Women for Warmer Weather and Beyond
5. First Ever National Biovigilance Network in the U.S. Reaches $1 Million in Funding, Prepares for Fall Pilot Launch
6. OrthoSynetics(TM) Expands Sales Team; Prepares to Grow
7. New Anti-Cellulite Treatment Prepares Women for Warmer Weather
8. Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon
9. Penn Foster Prepares Students to Meet Healthcare Employment Needs
10. Pieris Strengthens its Management, as it Prepares for the Clinical Development of PRS-050, an Anticalin(R)-Based Novel Cancer Therapy
11. Assessing the quality of phase I clinical trial abstracts
Post Your Comments:
Related Image:
CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two ... American children and adults, according to a new study by researchers at the School ... in Children and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers ...
(Date:11/30/2015)... ... ... Newly reviewed and approved “NJ Top Dentist”, Dr. Eugene Isola III, is ... in 1935. His father graduated from NYU School of Dentistry in 1965. ... their commitment and passion to the Practice of Dentistry. Continuing the family practice ...
(Date:11/30/2015)... New York, NY (PRWEB) , ... November 30, 2015 , ... ... New York Times,” will be released on December 1, 2015, to coincide with World ... book about the groundbreaking journalist who covered the AIDS epidemic as he was dying ...
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for ... honor of World AIDS Day 2015. On Nov. 30, ASCP shared its “Give a ... about World AIDS Day and the importance of getting tested for HIV. , ASCP ...
(Date:11/30/2015)... ... 30, 2015 , ... California-based i2i Systems, a pioneer defining ... Michigan-based Family Health Center (FHC) has selected i2iTracks as their population health management ... the largest Affordable Care Act grant for Federally Qualified Health Centers in the ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 iCAD, Inc. (Nasdaq: ... feature its latest solutions for advanced image analysis ... cancer at the Radiological Society of North American ... from November 29 to December 4, ... including iReveal®, an automated breast density assessment solution, ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare and ... Life Sciences Report 2015 . --> Pharmaboardroom releases its ... Latin America , a country of over ... a country of over 122 million people. --> It ... pharmaceuticals, or life sciences insights into the second largest pharma and ...
Breaking Medicine Technology: